Purepac Gabapentin 180-Day Exclusivity Award “Reasonable,” Judge Says
Executive Summary
FDA's determination that Purepac is eligible for 180-day generic exclusivity on gabapentin capsules (Pfizer's Neurontin) was reasonable and "an appropriate application of administrative discretion," D.C. federal court Judge Ellen Segal Huvelle ruled April 25
You may also be interested in...
Purepac’s Neurontin Generic Exclusivity, FDA’s “Section viii” Policy Affirmed
FDA's position on the appropriate use of "section viii" statements in ANDAs will stand following an appellate court ruling on gabapentin generics
Purepac’s Neurontin Generic Exclusivity, FDA’s “Section viii” Policy Affirmed
FDA's position on the appropriate use of "section viii" statements in ANDAs will stand following an appellate court ruling on gabapentin generics
Neurontin, Rebetol Generics Could Be Affected By “Shared Exclusivity” Ruling
A federal court decision invalidating FDA's "shared exclusivity" policy for first-to-file ANDAs poses another potential complication to the launch of generic versions of Pfizer's Neurontin (gabapentin)